Oryzon Genomics Overview
- Founded
-
2000
- Status
-
Public
- Employees
-
44
- Stock Symbol
-
ORY
- Investments
-
1
- Share Price
-
$2.30
- (As of Monday Closing)
Oryzon Genomics General Information
Description
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
MAD
Primary Office
- Sant Ferran 74
- Cornellà de Llobregat
- 08940 Barcelona
- Spain
+34 935 00 00 00
Oryzon Genomics Timeline
Oryzon Genomics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.30 | $2.29 | $1.94 - $3.25 | $128M | 55.6M | 214K | -$0.08 |
Oryzon Genomics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 146,078 | 146,078 | 134,689 | 187,910 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (5,554) | (5,554) | (7,786) | (4,747) |
| Net Income | (4,449) | (4,449) | (5,541) | (3,875) |
| Total Assets | 111,207 | 111,207 | 107,996 | 115,748 |
| Total Debt | 18,704 | 18,704 | 15,592 | 11,183 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Oryzon Genomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Oryzon Genomics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based the
Biotechnology
Barcelona, Spain
44
As of 2022
00000
000000000
00000
000000
rit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur si
0000000000000
Berkeley, CA
000
As of 0000
00000
0000
0000-00-00
00000000
00000
000000
sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labor
0000 000000000
Kulmbach, Germany
00
As of 0000
000000000000
Add Comparison
Oryzon Genomics Competitors (39)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | 000 | 00000 | 00000000 | 00000 |
| 0000000 | Private Equity-Backed | Kulmbach, Germany | 00 | 000000000000 | ||
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | Pittsburgh, PA | 0 | 00.000 | 0000000000 0 | 00.000 |
Oryzon Genomics Patents
Oryzon Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4025210-A1 | Vafidemstat for use in treating autism spectrum disorders | Pending | 03-Sep-2019 | 00000000000 | |
| US-20220288039-A1 | Vafidemstat for use in treating autism spectrum disorders | Inactive | 03-Sep-2019 | 00000000000 | |
| EP-3994280-A1 | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors | Pending | 05-Jul-2019 | 0000000000 | |
| CA-3142435-A1 | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors | Pending | 06-Jun-2019 | 0000000000 | |
| EP-3980416-A1 | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors | Pending | 06-Jun-2019 | C07D471/04 |
Oryzon Genomics Executive Team (17)
Oryzon Genomics Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Antonio Fornieles Melero | Oryzon Genomics | Board Member | 000 0000 |
| Carlos Buesa Ph.D | Oryzon Genomics | Chairman & Board Member | 000 0000 |
| Isabel Aguilera Navarro | Self | Board Member | 000 0000 |
| Tamara Maes Ph.D | Oryzon Genomics | Deputy Chairman & Board Member | 000 0000 |
Oryzon Genomics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Oryzon Genomics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 27-Jan-2009 | 0000000000 | Biotechnology | 000000 00 |
Oryzon Genomics ESG
Risk Overview
Risk Rating
Updated January, 31, 2023
28.71 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 899
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 401
Rank
00.00
Percentile
